ABVD | adriamycin, bleomycin, vinblastin, and dacarbazine |
ACA | Patient Protection and Affordable Care Act |
ALL | acute lymphoblastic leukemia |
ASCO | American Society of Clinical Oncology |
AYA | adolescent and young adult |
AYA HOPE |
Adolescent and Young Adult Health Outcomes and Patient Experience |
BRAF |
human homolog B of v-raf (rapidly accelerated fibrosarcoma viral oncogene) |
BRFSS | Behavioral Risk Factors and Surveillance System |
CCSS | Childhood Cancer Survivor Study |
CDC | Centers for Disease Control and Prevention |
CHLA | Children’s Hospital Los Angeles |
COG | Children’s Oncology Group |
CT | computed tomography |
DCIS | ductal carcinoma in situ |
HHS | U.S. Department of Health and Human Services |
HL | Hodgkin’s lymphoma |
HPV | human papillomavirus |
IDLE | indolent lesions of epithelial origin |
IOM | Institute of Medicine |
LIFE | Long-Term Information, Follow-Up and Evaluation |
MEPS | Medical Expenditure Panel Survey |
MOPP |
mustragen, oncovin [aka vincristine], procarbazine, and prednisone |
MRI | magnetic resonance imaging |
NCI | National Cancer Institute |
NCPF | National Cancer Policy Forum |
OHSU | Oregon Health & Science University |
PET | positron emission tomography |
PRG | NCI Progress Review Group |
SEER | Surveillance, Epidemiology and End Results |
TAC | Thriving After Cancer |
UCLA | University of California, Los Angeles |